177lu-dota-eb-fapi radionuclide therapy
Refractory Solid Tumor
The First Affiliated Hospital of Xiamen UniversityradiopharmaceuticalPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
180 Active assets in the Refractory Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Catequentinib Nanfang Hospital, Southern Medical University | Phase 3 | BB |
Irinotecan M.D. Anderson Cancer Center | Phase 2 | BB |
Durvalumab OHSU Knight Cancer Institute | Phase 2 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab CatalYm GmbH | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →